11 August 2021>: Clinical Research
Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center
Jianquan Zhu 1ABCDEF , Yu Zhang 1BC , Meng Wang 1BC , Zhenfa Zhang 1BC , Dongsheng Yue 1BC , Shichang Liu 2BC , Yi Pan 3BC , Changli Wang 1AE*DOI: 10.12659/MSM.930738
Med Sci Monit 2021; 27:e930738
Table 3 Surgical characteristics and endpoints of patients with squamous cell carcinoma of the lung treated with neoadjuvant nab-paclitaxel and carboplatin.
Variable | Surgery (n=23) |
---|---|
R0 resection, n (%) | 22 (95.7) |
Adjuvant chemotherapy, n (%) | 21 (91.3) |
Type of surgery, n (%) | |
Lobectomy | 16 (69.6) |
Bilobectomy | 3 (13.0) |
Pneumonectomy | 4 (17.4) |
pCR 1, (%)* | 2 (8.7) |
pCR 2, (%)** | 2 (8.7) |
MPR, (%) | 8 (34.8) |
Downstage, (%) | 11 (47.8) |
MPR – major pathological response; pCR – pathological complete response; R0 – margin-free. * pCR 1 represented the proportion of patients with pCR when considering the tumor only; ** pCR 2 represented the proportion of patients with pCR when considering the tumor and lymph nodes. |